12:48 PM EDT, 06/11/2025 (MT Newswires) -- AbbVie ( ABBV ) said Wednesday the US Food and Drug Administration granted a label expansion for Mavyret to treat patients suffering from hepatitis C virus.

The approval was based on phase 3 trial data on the safety and efficacy of the oral eight-week pangenotypic direct acting antiviral therapy, the company said.

The approval will enable health providers to treat patients immediately at the time of diagnosis, according to a statement.

The FDA also granted a breakthrough therapy designation for Mavyret to treat acute HCV, according to the company.

Shares were up 1.4% in recent trading.

Price: 192.24, Change: +2.74, Percent Change: +1.44